Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Operating Leases (2019 - 2026)

Apyx Medical filings provide 7 years of Operating Leases readings, the most recent being $4.5 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 0.56% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 million, a 0.56% decrease, with the full-year FY2025 number at $4.5 million, down 0.56% from a year prior.
  • Operating Leases hit $4.5 million in Q4 2025 for Apyx Medical, up from $4.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.4 million in Q2 2023 to a low of $30000.0 in Q3 2021.
  • Median Operating Leases over the past 5 years was $4.3 million (2025), compared with a mean of $3.0 million.
  • Biggest five-year swings in Operating Leases: plummeted 80.39% in 2021 and later soared 1413.33% in 2022.
  • Apyx Medical's Operating Leases stood at $30000.0 in 2021, then surged by 1466.67% to $470000.0 in 2022, then surged by 941.7% to $4.9 million in 2023, then decreased by 8.44% to $4.5 million in 2024, then dropped by 0.56% to $4.5 million in 2025.
  • The last three reported values for Operating Leases were $4.5 million (Q4 2025), $4.2 million (Q3 2025), and $4.3 million (Q2 2025) per Business Quant data.